Figure 3From: G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to Raltegravir whereas Y143C does notIn vitro enzymatic activity of HIV-2 INs. 3'-processing (3'-P) and strand stranfer (ST) activities of the mutants are normalized and represented as percentage of activity wild-type B-type sequence of INI-naïve patient N1 that was taken as a reference for HIV-2 IN activity. A/INs amplified from HIV-2 infected patients. B/INs harboring mutations obtained by site-directed mutagenesis in N1 background.Back to article page